DK3852617T3 - Anvendelse af antistof fragmenter til revertering af ticagrelor-aktivitet - Google Patents
Anvendelse af antistof fragmenter til revertering af ticagrelor-aktivitetInfo
- Publication number
- DK3852617T3 DK3852617T3 DK19863329.9T DK19863329T DK3852617T3 DK 3852617 T3 DK3852617 T3 DK 3852617T3 DK 19863329 T DK19863329 T DK 19863329T DK 3852617 T3 DK3852617 T3 DK 3852617T3
- Authority
- DK
- Denmark
- Prior art keywords
- ticagrelor
- reverse
- activity
- antibody fragments
- fragments
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862733892P | 2018-09-20 | 2018-09-20 | |
| US201962806225P | 2019-02-15 | 2019-02-15 | |
| US201962836373P | 2019-04-19 | 2019-04-19 | |
| PCT/US2019/052173 WO2020061465A1 (en) | 2018-09-20 | 2019-09-20 | Methods of reversing ticagrelor activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3852617T3 true DK3852617T3 (da) | 2025-10-20 |
Family
ID=69887913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19863329.9T DK3852617T3 (da) | 2018-09-20 | 2019-09-20 | Anvendelse af antistof fragmenter til revertering af ticagrelor-aktivitet |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12617870B2 (enExample) |
| EP (2) | EP3852617B1 (enExample) |
| JP (2) | JP7478975B2 (enExample) |
| KR (2) | KR20250161038A (enExample) |
| CN (1) | CN113194821B (enExample) |
| AU (1) | AU2019342755B2 (enExample) |
| CA (1) | CA3113654A1 (enExample) |
| DK (1) | DK3852617T3 (enExample) |
| ES (1) | ES3042247T3 (enExample) |
| FI (1) | FI3852617T3 (enExample) |
| MX (1) | MX2021003298A (enExample) |
| PL (1) | PL3852617T3 (enExample) |
| WO (1) | WO2020061465A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2021125449A (ru) | 2014-10-01 | 2021-09-16 | Медиммьюн Лимитед | Антитела к тикагрелору и способы применения |
| EP3852617B1 (en) * | 2018-09-20 | 2025-09-10 | SFJ Pharma X, Inc. | Use of antibody fragments for reversing ticagrelor activity |
| WO2022240754A2 (en) * | 2021-05-10 | 2022-11-17 | Phasebio Pharmaceuticals, Inc. | Pharmacokinetic & pharmacodynamic model for determining effective dose of anti-ticagrelor antibody |
| KR102952285B1 (ko) | 2021-07-13 | 2026-04-13 | 주식회사 엘지에너지솔루션 | 전지의 용접 상태 검사 방법 |
| WO2026019858A1 (en) * | 2024-07-16 | 2026-01-22 | SFJ Pharma X, Inc. | Methods of reversing ticagrelor activity |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| JPH03154867A (ja) * | 1989-11-13 | 1991-07-02 | Teijin Ltd | １―メチルアデノシンの免疫学的測定方法，そのための測定試薬及び試薬キット |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
| JPH07503124A (ja) | 1991-06-14 | 1995-04-06 | ゾーマ・コーポレーション | 微生物によって生産される抗体断片とそれらの複合体 |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| JPH09506262A (ja) | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
| ES2201097T3 (es) | 1994-01-31 | 2004-03-16 | Trustees Of Boston University | Bibliotecas de anticuerpos policlonales. |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| AR017014A1 (es) | 1997-07-22 | 2001-08-22 | Astrazeneca Ab | Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos |
| TWI229674B (en) | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
| US7029872B2 (en) | 2000-06-28 | 2006-04-18 | Glycofi, Inc | Methods for producing modified glycoproteins |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| JP2006512102A (ja) | 2002-04-11 | 2006-04-13 | メディミューン・ヴァクシンズ・インコーポレーテッド | 噴霧乾燥による生物活性材料の防腐 |
| WO2003087339A2 (en) | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for pulmonary administration |
| EP1494651A4 (en) | 2002-04-11 | 2010-10-13 | Medimmune Vaccines Inc | PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM |
| US20040042972A1 (en) | 2002-04-11 | 2004-03-04 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for intranasal administration |
| KR20050088175A (ko) | 2002-12-17 | 2005-09-02 | 메드이뮨 백신즈 인코포레이티드 | 생물활성 물질의 고압 분무 건조 |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| MX2008009220A (es) | 2006-01-17 | 2008-10-10 | Biolex Therapeutics Inc | Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas. |
| TWI391378B (zh) | 2006-03-16 | 2013-04-01 | Astellas Pharma Inc | 喹啉酮衍生物或其製藥學上可被容許之鹽 |
| NZ574804A (en) | 2006-08-11 | 2012-02-24 | Schering Corp | Antibodies to il-17a |
| CL2007002668A1 (es) | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
| EP1995309A1 (en) | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
| CN101952312A (zh) | 2007-07-31 | 2011-01-19 | 米迪缪尼有限公司 | 多特异性表位结合蛋白及其应用 |
| JP2014516982A (ja) * | 2011-06-01 | 2014-07-17 | アストラゼネカ アクチボラグ | 新規なチカグレロル共結晶 |
| EP2729488A4 (en) | 2011-07-06 | 2015-01-14 | Medimmune Llc | PROCESS FOR PREPARING MULTIMANT POLYPEPTIDES |
| IN2014CN02806A (enExample) | 2011-10-14 | 2015-07-03 | Bristol Myers Squibb Co | |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| US10000565B2 (en) * | 2012-11-16 | 2018-06-19 | Novartis Ag | Use of IL-1 β binding antibodies for treating peripheral arterial disease |
| HK1219044A1 (zh) * | 2013-03-15 | 2017-03-24 | 艾伯维德国有限责任两合公司 | 抗egfr抗体药物偶联物制剂 |
| US10259842B2 (en) * | 2013-05-15 | 2019-04-16 | Medimmune, Llc | Purification of recombinantly produced polypeptides |
| US20150313595A1 (en) | 2014-05-02 | 2015-11-05 | W. L. Gore & Associates, Inc. | Anastomosis Devices |
| WO2016033424A1 (en) * | 2014-08-29 | 2016-03-03 | Genzyme Corporation | Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b |
| RU2021125449A (ru) | 2014-10-01 | 2021-09-16 | Медиммьюн Лимитед | Антитела к тикагрелору и способы применения |
| JP2018502894A (ja) * | 2015-01-27 | 2018-02-01 | アストラゼネカ アクチボラグ | 心筋梗塞の病歴がある患者においてアテローム血栓性イベントを治療または予防する方法 |
| KR101916956B1 (ko) * | 2016-12-13 | 2018-11-08 | 보령제약 주식회사 | 티카그렐러의 신규한 고체 형태 및 이의 제조방법 |
| CN118320078A (zh) * | 2016-12-23 | 2024-07-12 | 诺华股份有限公司 | 采用抗因子XI/XIa抗体治疗的方法 |
| JP2020509025A (ja) * | 2017-03-01 | 2020-03-26 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | モノクローナル抗体製剤 |
| EP3852617B1 (en) | 2018-09-20 | 2025-09-10 | SFJ Pharma X, Inc. | Use of antibody fragments for reversing ticagrelor activity |
| WO2022240754A2 (en) | 2021-05-10 | 2022-11-17 | Phasebio Pharmaceuticals, Inc. | Pharmacokinetic & pharmacodynamic model for determining effective dose of anti-ticagrelor antibody |
-
2019
- 2019-09-20 EP EP19863329.9A patent/EP3852617B1/en active Active
- 2019-09-20 WO PCT/US2019/052173 patent/WO2020061465A1/en not_active Ceased
- 2019-09-20 FI FIEP19863329.9T patent/FI3852617T3/fi active
- 2019-09-20 US US17/278,075 patent/US12617870B2/en active Active
- 2019-09-20 AU AU2019342755A patent/AU2019342755B2/en active Active
- 2019-09-20 EP EP25193499.8A patent/EP4653465A3/en active Pending
- 2019-09-20 KR KR1020257035868A patent/KR20250161038A/ko active Pending
- 2019-09-20 DK DK19863329.9T patent/DK3852617T3/da active
- 2019-09-20 JP JP2021515473A patent/JP7478975B2/ja active Active
- 2019-09-20 MX MX2021003298A patent/MX2021003298A/es unknown
- 2019-09-20 PL PL19863329.9T patent/PL3852617T3/pl unknown
- 2019-09-20 CN CN201980075991.0A patent/CN113194821B/zh active Active
- 2019-09-20 CA CA3113654A patent/CA3113654A1/en active Pending
- 2019-09-20 ES ES19863329T patent/ES3042247T3/es active Active
- 2019-09-20 KR KR1020217011614A patent/KR102880762B1/ko active Active
-
2024
- 2024-04-09 JP JP2024062468A patent/JP2024096134A/ja active Pending
-
2026
- 2026-04-01 US US19/636,775 patent/US20260209389A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020061465A1 (en) | 2020-03-26 |
| EP4653465A2 (en) | 2025-11-26 |
| US20260209389A1 (en) | 2026-07-23 |
| EP4653465A3 (en) | 2026-01-07 |
| JP7478975B2 (ja) | 2024-05-08 |
| EP3852617A1 (en) | 2021-07-28 |
| US20210347915A1 (en) | 2021-11-11 |
| EP3852617B1 (en) | 2025-09-10 |
| ES3042247T3 (en) | 2025-11-19 |
| FI3852617T3 (fi) | 2025-10-21 |
| KR20250161038A (ko) | 2025-11-14 |
| AU2019342755B2 (en) | 2025-12-11 |
| CN113194821A (zh) | 2021-07-30 |
| JP2022501368A (ja) | 2022-01-06 |
| PL3852617T3 (pl) | 2026-01-26 |
| EP3852617A4 (en) | 2022-08-24 |
| JP2024096134A (ja) | 2024-07-12 |
| AU2019342755A1 (en) | 2021-05-06 |
| KR102880762B1 (ko) | 2025-11-03 |
| CN113194821B (zh) | 2025-07-04 |
| CA3113654A1 (en) | 2020-03-26 |
| KR20210091698A (ko) | 2021-07-22 |
| MX2021003298A (es) | 2021-08-11 |
| US12617870B2 (en) | 2026-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2021000112A (es) | Compuestos de pirrolizina sustituida y usos de los mismos | |
| IL283427A (en) | Empirical variant score (evs)-based variant caller | |
| EP3857879A4 (en) | SIMPLIFICATION OF COMBINED INTER-INTRA PREDICTION | |
| DK3428274T3 (da) | Anvendelse af nukleosominteragerende proteindomæner til forbedring af målrettet genommodifikation | |
| IL259713A (en) | Anti-dr5 antibodies and methods of use thereof | |
| PL3303396T3 (pl) | Przeciwciała przeciwko ox40 i ich zastosowanie | |
| PT3282835T (pt) | Ratinhos knockin de sirpa-il15 humanizadas e métodos de utilização dos mesmos | |
| PL3250610T3 (pl) | Przeciwciała anty-FcRn i sposoby ich stosowania | |
| IL283968A (en) | Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | |
| DK3261721T3 (da) | Anvendelse af pridopidin til forbedring af hukommelse | |
| PT3280440T (pt) | Anticorpos anti-c1s humanizados e métodos de utilização destes | |
| PT3463435T (pt) | Anticorpos para alfa-sinucleína e as suas utilizações | |
| DK3319989T3 (da) | Anvendelse af modificerede fc-fragmenter i immunterapi | |
| IL283782A (en) | Anellosomes and methods of use | |
| CR20180296A (es) | ANTICUERPOS ANTI-HtrA1 Y MÉTODOS DE USO | |
| EP3895023A4 (en) | MACRO OP FUSION | |
| SV2018005624A (es) | Anticuerpos anti-cd154 y metodos de uso de estos | |
| IL283136A (en) | Antibodies to mucin-16 and methods of use thereof | |
| IL281976A (en) | Anti-fgfr2 antibody formulations | |
| EP3472053A4 (en) | CONVERSION AND APPLICATION OF MATERIAL STRIPS | |
| IL284880A (en) | Liver-specific inducible promoters and methods of use thereof | |
| DK3500586T3 (da) | Kontinuerlig fremgangsmåde til at reducere heterogenitet af terapeutisk protein | |
| FR3042983B1 (fr) | Reflux de colonnes de demethanisation | |
| DK3174861T3 (da) | Substituerede bicykliske dihydropyrimidinoner og deres anvendelse som inhibitorer af neutrofil elastaseaktivitet | |
| IL285119A (en) | Use of spiropidion |